Emergent Health to Enter the Projected $60 Billion Global Anti-Aging Market

KING OF PRUSSIA, PA / ACCESSWIRE / February 3, 2022 / Emergent Health Corp., (OTC PINK:EMGE) announces entering the projected $60 Billion global anti-aging market with the introduction of its newest product “Infinity Plus Multi™”, a unique proprietary product that targets Adult Stem Cell Support, Telomere Support and Specialized Ant-Aging Oxidants. Infinity Plus Multi™ is currently in production and scheduled for delivery next month.

TextDescription automatically generated

According to Brandessence market research, the anti-aging market size is likely to witness robust growth at a CAGR of 5.3% during the 2021-2028 period. The anti-aging market size reached a valuation of USD $42.46 billion in 2020 and is likely to grow to USD $60.95 billion by 2027 end. Further information can be found at Brandessence Anti-Aging Market Report.

Adult Stem Cell Support is required because as we age our adult stem cell production declines. Adult stem cells are required to assist in rebuilding organs and tissue. Without an adequate supply longevity and morbidity could be affected. Infinity Plus Multi™ responds to this negative feature. Telomere Support is required as Telomeres are the tips of chromosomes in DNA. As they get shorter, longevity and morbidity are also affected. Infinity Plus Multi™ addresses this issue. Specialized anti-aging oxidants are required as they enhance the quality and length of life. Emergent plans to market Infinity Plus Multi™ through forced matrix, a special type of network marketing geared to networkers who don’t recruit much. The anticipated retail price is $49.99, which management believes is considerably less than any competitor with a comparable product.

The number and quality of our stem cells declines as we age, making the body more susceptible to age-related health challenges. In addition, environmental toxins, stress, lack of sleep and a poor diet all create a negative impact on our body’s natural stem cell system of repair. The unique combination of natural compounds in Infinity Plus Multi™ supports our stem cell’s ability to repair, renew, and restore tissues and organ function through healthy stem cell Release, Circulation, and Migration, and allows all other systems of the body to function on more optimum and healthy levels.

The novel combination of highly potent and fast-acting anti-aging oxidants such as Curcumin. Silymarin, Resveratrol, Astragalus polysaccharides, Astragaloside IV, L-Carnosine, Vitamin C and Trimethylglycine are inluded in the formula.

Dr. John V. Cappello, President of Emergent stated “This innovative product utilizes the most recent research advancements on all-natural ingredients to create a synergistic, highly bioavailable, safe, and powerful formula like no other we’re aware of. We’re very excited about the future market potential.”


Emergent Health Corp. (www.emergenthealthcorp.com) is developing and marketing natural stem cell mobilizing agents and diet aids designed to help control hunger through normal body signals to the brain and stomach for the consumer and professional markets. PharmaZu Corp., its newly acquired subsidiary is a pure play, e-commerce products and service provider focused on the pet pharmacy, vet telehealth and pet wellness businesses. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease.


This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company’s control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


James Zimbler